Form 4: Crescent Biopharma Director Receives Stock Options

Director Alexandra Balcom was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity incentive.

Summary

• Director Alexandra Balcom acquired 11,050 stock options in Crescent Biopharma, Inc. (CBIO).
• The options have an exercise price of $17.01 per share.
• The grant date for these options is June 2, 2026.
• The options are set to expire on June 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is contingent upon the company's share price exceeding the $17.01 exercise price.

Future Outlook

The options vest in full on the earlier of June 2, 2027, or the date of the next annual meeting of shareholders, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to attract and retain board talent, aligning governance with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biopharmaceutical companies.
• The use of a one-year cliff vesting period is a standard retention mechanism in the industry.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised.

Next Steps

• Vesting of options on June 2, 2027, or the next annual meeting of shareholders.

Key Dates

Keywords

Crescent Biopharma, CBIO, Form 4, Insider Trading, Stock Options, Director Compensation